The comparative analysis revealed that the labeling parameters [EGFR(+), HX103(+) or EGFR(+)HX103(+)] showed a statistically significant difference between tumor samples with EGFR-activating mutations and wild-type (Supplementary Figs. 23–25). The gene discussed is EGFR; the disease is neoplasm.